Eyevensys has added $12m to its coffers, having previously procured $30m in a series B round backed by Inserm Transfert in early 2020.
Eyevensys, a France-based eye disease therapy developer based on research at Paris Descartes University, has picked up $12m in a series B-plus round led by Korea Investment Partners.
Unnamed, existing backers also took part in the round.
Founded in 2008, Eyevensys is working on non-viral gene therapies for retinal and ophthalmological diseases. It will use the money to advance its programmes, including a potential treatment for wet age-related macular degeneration.
Patricia Zilliox, CEO of Eyevensys, said: “We are thrilled to announce this funding round, which will help us move forward in our mission to develop life-changing solutions for patients with debilitating eye diseases.
“We are also excited to have the support of Korea Investment Partners and our existing investors as we pivot to refocus on our additional programs focused on wet AMD and retinitis pigmentosa.
“This funding will allow us to demonstrate that treating ophthalmic conditions does not have to be invasive and risky, and that our approach is more convenient than other intraocular drug delivery approaches.”
Inserm Transfert Initiative, the tech transfer arm of research institute Inserm, backed a $30m series B round in January 2020 that was led by Boehringer Ingelheim Venture Fund, the corporate venturing arm of pharmaceutical firm Boehringer Ingelheim.
Bpifrance, Pontifax Venture Capital, CapDecisif, Global Health Sciences Fund and Pureos Bioventures also invested as part of the series B round. The company has now raised $54.1m altogether.
